Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain CLVS message board posts where the ticker symbol CLVS has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest CLVS SEC Filings

Filings Format Description Filing Date File/Film Number
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0000899243-18-004457 Size: 4 KB
2018-02-16
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001306923-18-000004 (34 Act)  Size: 50 KB
2018-02-14 005-86488
18614594
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001144204-18-008969 (34 Act)  Size: 145 KB
2018-02-14 005-86488
18613171
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000950142-18-000424 (34 Act)  Size: 148 KB
2018-02-14 005-86488
18612224
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001085146-18-000750 (34 Act)  Size: 54 KB
2018-02-14 005-86488
18608212
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000093751-18-000062 (34 Act)  Size: 8 KB
2018-02-13 005-86488
18602033
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000932471-18-003197 (34 Act)  Size: 45 KB
2018-02-09 005-86488
18587207
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000215457-18-005022 (34 Act)  Size: 13 KB
2018-02-08 005-86488
18583077
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0000038777-18-000056 (34 Act)  Size: 208 KB
2018-02-06 005-86488
18576835
SC 13G/A  Documents [Amend] Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001319244-18-000015 (34 Act)  Size: 142 KB
2018-01-30 005-86488
18559795
More CLVS SEC Filings


Related news from
Mon, 19 Feb 2018
13:04:11 +0000
See what the IHS Markit Score report has to say about Clovis Oncology Inc.
Short interest is moderately high for CLVS with between 10 and 15% of shares outstanding currently on loan. The net inflows of $198 million over the last one-month into ETFs that hold CLVS are among the lowest of the last year and appear to be slowing.
Mon, 12 Feb 2018
21:05:00 +0000
Clovis Oncology to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 26
Clovis Oncology, Inc. will announce its fourth quarter and full year 2017 financial results on Monday, February 26, 2018, after the close of the U.S. financial markets.
Mon, 22 Jan 2018
14:42:02 +0000
AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan
AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.
Fri, 12 Jan 2018
13:20:00 +0000
Today’s Research Reports on Trending Tickers: Clovis Oncology and Incyte Corporation
NEW YORK, NY / ACCESSWIRE / January 12, 2017 / U.S. markets rallied sharply Thursday as investor focus has now shifted to the upcoming earnings season. The Dow Jones Industrial Average jumped 0.81 percent ...
Fri, 05 Jan 2018
21:39:27 +0000
Why These 3 Biotech Stocks Could Outperform Their Peers In 2018
Puma, Clovis and Incyte could outperform other midcap biotechs this year, an analyst says, listing the trio as his favorites for 2018.
Thu, 04 Jan 2018
13:00:00 +0000
Clovis Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
Clovis Oncology, Inc. today announced that its Chief Executive Officer and President, Patrick J. Mahaffy, will present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 PM Pacific Time.
Thu, 28 Dec 2017
14:10:02 +0000
Clovis Up More Than 50% in 2017: What's Driving the Stock?
Clovis Oncology (CLVS) stock is rapidly gaining momentum. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Tue, 19 Dec 2017
13:00:00 +0000
Rucaparib MAA for the Ovarian Cancer Treatment Indication Referred by CHMP to Scientific Advisory Group on Oncology for Review Expected in February 2018
Clovis Oncology, Inc. announced today that the European Union’s European Medicines Agency Committee for Medicinal Products for Human Use has requested that the Scientific Advisory Group on Oncology provide an opinion on aspects of the ongoing Marketing Authorization Application relating to a potential conditional approval for rucaparib.
Fri, 15 Dec 2017
08:00:00 +0000
Clovis Oncology Shows Rising Relative Strength; Still Shy Of Key Threshold
Clovis Oncology shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Wed, 13 Dec 2017
17:41:05 +0000
Value Biotech ETFs to Buy Now
A few reasons why you should buy value biotech ETFs for 2018
Wed, 06 Dec 2017
20:09:08 +0000
Clovis' sNDA for Rubraca Gets Priority Review in the U.S.
The FDA grants priority review to Clovis' (CLVS) supplemental new drug application for its marketed drug, Rubraca's label expansion as a maintenance treatment for ovarian cancer.
Wed, 06 Dec 2017
19:08:47 +0000
Why Clovis' Good News In Ovarian Cancer Prodded These Rivals Down
Clovis rose Wednesday to the detriment of Tesaro and AstraZeneca after the FDA accepted its application for expanded use of its PARP inhibitor known as Rubraca.
Wed, 06 Dec 2017
14:30:00 +0000
Clovis Up on Priority Review Status for Ovarian Cancer Therapy -- Biotech Mover
The FDA has accepted the Boulder, Colo.-based firm's supplemental New Drug Application for ovarian cancer therapy rucaparib and granted priority review status to the application.
Wed, 06 Dec 2017
12:46:12 +0000
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data
Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.
Wed, 06 Dec 2017
01:25:11 +0000
Clovis Oncology gets FDA fast-tracked review date for ovarian cancer drug
The U.S. Food and Drug Administration has granted a fast-tracked review of using a Clovis Oncology drug to treat a wider range of ovarian cancer patients. The Boulder-based company (CLVS) seeks approval to use its ovarian cancer drug, rucaparib, as a maintenance treatment in women “with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are platinum sensitive” and regardless of their genetic profile. The FDA says it will make a decision by April 6, 2018, Clovis announced Tuesday.
Tue, 05 Dec 2017
21:05:00 +0000
Clovis Announces Priority Review Designation for Rucaparib Supplemental New Drug Application
Clovis Oncology announced today that the U.S. Food and Drug Administration has accepted the company’s supplemental New Drug Application for rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act date of April 6, 2018.
Tue, 28 Nov 2017
16:58:00 +0000
Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte
After a very strong year, the biotech sector has suffered an 8% pullback over the past 5 weeks. Todd Hagopian, whose biotech portfolio is up 38% this year, believes that the recent pullback has created bargains in Alexion, Flexion, Clovis, Tesaro, and Incyte.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "I have been a VF subscriber for one year and have found the members here generally to be informed, intelligent, articulate people of good will. The knowledge I've gathered has been well worth the price of tuition, and the subscription fee has been repaid many-fold in investment gains." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards